Trial record 1 of 1 for:
NCT03350321
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects (MIYABI ND-C)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03350321 |
|
Recruitment Status :
Completed
First Posted : November 22, 2017
Last Update Posted : January 29, 2021
|
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anemia Renal Insufficiency, Chronic | Drug: Molidustat (BAY85-3934) Drug: Darbepoetin alfa | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 162 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Non-dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs) |
| Actual Study Start Date : | December 12, 2017 |
| Actual Primary Completion Date : | May 17, 2019 |
| Actual Study Completion Date : | October 11, 2019 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Anemia
Drug Information available for:
Darbepoetin Alfa
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Molidustat (BAY85-3934)
Molidustat group
|
Drug: Molidustat (BAY85-3934)
Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response |
|
Active Comparator: Darbepoetin alfa
Darbepoetin alfa group
|
Drug: Darbepoetin alfa
Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response |
Primary Outcome Measures :
- Mean Hb (Hemoglobin) level [ Time Frame: From week 30 to 36 ]
- Change in hemoglobin level from baseline to the average during the evaluation period [ Time Frame: Baseline and week 30 to 36 ]
Secondary Outcome Measures :
- Responder rate: proportion of responders among the subjects [ Time Frame: From week 30 to 36 ]
Responder is defined as meeting all of the following criteria:
(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment
- Rate of rise in Hb (Hemoglobin) level (g/dL/week) [ Time Frame: Up to 8 weeks ]
- Rate of rise in Hb (Hemoglobin) level (g/dL/week) [ Time Frame: Up to 4 weeks ]
- Proportion of subjects who meet each component of the response [ Time Frame: From week 30 to 36 ]
Response:
(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment
- Cumulative proportion of subjects who achieve the lower limit of the target Hb range at least once [ Time Frame: Up to 52 weeks ]
- Change in Hb level [ Time Frame: Baseline and up to 52 weeks ]
- Hb level [ Time Frame: Baseline and up to 52 weeks ]
- Proportion of subjects whose mean hemoglobin level is in the target range [ Time Frame: From week 30 to 36 ]
- Proportion of subjects whose mean hemoglobin level is above the target range [ Time Frame: From week 30 to 36 ]
- Proportion of subjects whose mean hemoglobin level is below the target range [ Time Frame: From week 30 to 36 ]
- Proportion of subjects with hemoglobin levels in the target range [ Time Frame: Up to 52 weeks ]
- Proportion of subjects with hemoglobin levels above the target range [ Time Frame: Up to 52 weeks ]
- Proportion of subjects with hemoglobin levels below the target range [ Time Frame: Up to 52 weeks ]
- Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week [ Time Frame: Up to 52 weeks ]Defined as change in Hb level / duration between two visits (weeks)
- Number of participants with serious adverse events [ Time Frame: Up to 52 weeks ]
- Maximum concentration (Cmax) [ Time Frame: At baseline, week 12, week 24 and week 52 ]
- Area under the concentration-time curve (AUC) [ Time Frame: At baseline, week 12, week 24 and week 52 ]
- EPO (Erythropoietin) serum concentration [ Time Frame: At baseline, week 12, week 24 and week 52 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects with estimated glomerular filtration rate (eGFR)< 60 mL/min/1.73m^2 (Chronic kidney disease [CKD] stages 3 to 5)
- Body weight > 40 and ≤ 160 kg at screening
- Male or female subject ≥ 20 years of age at screening
- Not on dialysis and not expected to start dialysis during the study period
- Not treated with ESAs and/or HIF-PH inhibitors within 8 weeks prior to randomization
- Mean of the last 2 central laboratory Hb levels during the screening period must be ≥ 8.0 and < 11.0 g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the 2 measurements must be < 1.2 g/dL) and the last measurements must be taken within 14 days prior to randomization
- Ferritin ≥ 50 ng/mL at screening
Exclusion Criteria:
- New York Heart Association (NYHA) Class III or IV congestive heart failure
- History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization
- Sustained and poorly controlled arterial hypertension (defined as systolic BP≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP < 90mmHg) at randomization
- Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03350321
Locations
Show 61 study locations
Sponsors and Collaborators
Bayer
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bayer |
| ClinicalTrials.gov Identifier: | NCT03350321 |
| Other Study ID Numbers: |
19349 |
| First Posted: | November 22, 2017 Key Record Dates |
| Last Update Posted: | January 29, 2021 |
| Last Verified: | January 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Renal Insufficiency Renal Insufficiency, Chronic Anemia Hematologic Diseases |
Kidney Diseases Urologic Diseases Darbepoetin alfa Hematinics |